NCT01127451 2022-04-13
Study of Denileukin Diftitox in Participants With Stage IIIC and Stage IV Melanoma
Eisai Inc.
Phase 2 Completed
Clinical Trials
3 trialsNCT01401530 2018-11-23
E7777 for the Treatment of Patients With Peripheral T-Cell Lymphoma
Eisai Inc.
Phase 1 Completed
NCT01432483 2015-01-26
Access Program With Denileukin Diftitox for the Treatment of Patients Currently Receiving Treatment With Commercially Available (Ontak)
Eisai Inc.
No longer available